Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

Mes dernières consult.
Most popular
Real-time Quote. Real-time BATS EXCHANGE - 03/19 06:29:05 pm
76.6900 USD   -3.82%
03/15GILEAD SCIENCES : Norbert Bischofberger, PhD, to Step Down, John McH..
03/15GILEAD SCIENCES : Ex-dividend day for
03/14GILEAD SCIENCES : Grants Awarded to 13 Canadian Initiatives to Help ..
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 11:07am CET

Release date- 05102017 - FOSTER CITY, Calif. - Gilead Sciences, Inc.(NASDAQ: GILD) announced today a new licensing agreement with the Medicines Patent Pool (MPP), a United Nations-backed public health organization, to expand access to bictegravir (BIC) upon regulatory approval in the United States.

BIC is a novel investigational integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Through this agreement, MPP can sub-license rights to BIC to generic drug companies in India, China and South Africa to manufacture therapies containing BIC for distribution in 116 low- and middle-income countries.

Gilead has also expanded its licensing agreements with Sun Pharmaceutical Industries Limited, Strides Shasun Limited, Mylan Laboratories Limited and SeQuent Scientific Limited to include BIC, and products incorporating the compound, for distribution in 116 developing countries.

Under these voluntary licensing agreements, the manufacturers may produce BIC as a single agent or in fixed-dose combinations with other HIV medicines. BIC is the fifth HIV agent to be licensed in Gilead's agreements with the MPP and generic manufacturers. Gilead and the MPP recently expanded the geographic scope of the licensing agreements for Gilead's other HIV therapies to include Malaysia, Philippines, Ukraine and Belarus.

'These agreements allow for our licensees to provide generic versions of our latest therapies to people living with HIV in the developing world,' said Gregg H. Alton, Executive Vice President for Corporate and Medical Affairs at Gilead Sciences. 'Today, more than 10 million people in resource-limited countries are on Gilead-based HIV therapies, which would not be possible without these strong alliances.'

Voluntary licensing agreements are a key component of Gilead's efforts to increase access to the company's therapies in the developing world. Competition among manufacturers has reduced the lowest price of a Gilead HIV generic therapy by 80 percent since 2006, to as low as $3.50 per patient per month. Ninety-nine percent of people taking Gilead's HIV therapies in developing countries receive generic medicine.

Gilead has filed a New Drug Application to the U.S. Food and Drug Administration for an investigational, once-daily single tablet regimen containing BIC (50mg) and emtricitabine/tenofovir alafenamide (200mg/25mg) (BIC/FTC/TAF). In the European Union, the company's Marketing Authorization Application for BIC/FTC/TAF has been fully validated and is now under evaluation by the European Medicines Agency.

BIC in combination with FTC/TAF as a single tablet regimen is an investigational treatment that has not been determined to be safe or efficacious and is not approved anywhere globally.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it's estimated that more than 10 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company's manufacturing partners.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that regulatory authorities may not approve BIC/FTC/TAF in the currently anticipated timelines, and marketing approvals, if granted, may have significant limitations on their use. As a result, BIC/FTC/TAF may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.


Sung Lee

Tel: 650-524-7792

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES
03/15GILEAD SCIENCES : Researchers from Gilead Sciences Describe Findings in Hepatiti..
03/15GILEAD SCIENCES : Patent Issued for Apoptosis Signal-Regulating Kinase Inhibitor..
03/15GILEAD SCIENCES : Announces Data from New Preclinical Study Evaluating a Combina..
03/15GILEAD SCIENCES : New HIV/AIDS Findings from Gilead Sciences Described (Viral bl..
03/15GILEAD SCIENCES : Broadly neutralizing antibody treatment may target viral reser..
03/15GILEAD SCIENCES' : Norbert Bischofberger, PhD, to Step Down, John McHutchison, M..
03/15SPRING BANK PHARMACEUTICALS : Announces Presentation of Combined Inarigivir 25 m..
03/15GILEAD SCIENCES : Ex-dividend day for
03/14GILEAD SCIENCES : Grants Awarded to 13 Canadian Initiatives to Help Advance the ..
03/13GILEAD SCIENCES : Quebec Expands Patient Access to Chronic Hepatitis C Therapies
More news
News from SeekingAlpha
03/19BIOTECH BIO SERIES #2 : Is Gilead Still A Growth Stock? 
03/18TOPS OF 44 'SAFER' DIVIDEND NASDAQ E : Comcast By Gain; Vodafone By Yield For Ma.. 
03/18BY THE NUMBERS : Best Stocks In The Nasdaq 100 
03/17Top 52 Nasdaq Stocks By Yield, Upside & Gains For March 
03/16SPECIALTY RESEARCH : What The Lucrative NASH Market Has In Store 
Financials ($)
Sales 2018 21 296 M
EBIT 2018 11 173 M
Net income 2018 6 946 M
Debt 2018 14 498 M
Yield 2018 2,83%
P/E ratio 2018 14,81
P/E ratio 2019 14,14
EV / Sales 2018 5,59x
EV / Sales 2019 5,68x
Capitalization 104 B
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 88,9 $
Spread / Average Target 12%
EPS Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington Chief Financial Officer & Executive Vice President
Gregg H. Alton Executive VP-Corporate & Medical Affairs
Andrew Cheng Executive VP-Clinical Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.31%104 156
GENMAB22.93%12 773
BLUEBIRD BIO INC12.18%10 729
BEIGENE LTD (ADR)61.84%8 264